ArticleGels (Basel, Switzerland)2025
Liposomes-in-Gel as the Docetaxel Delivery for the Effective Treatment of Psoriasis by Inhibiting the Proliferation of Blood Vessels.
Article in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic skin disease caused by the interaction of multiple factors that leads to the abnormal growth of stratum corneum cells and has been called an immortal cancer. Docetaxel has been trialed for the treatment of psoriasis due to its superior ability to induce apoptosis, but its insolubility and low bioavailability have hampered its development. Here, docetaxel (DTX)-loaded liposomes-in-gel (DTX-LP-G) as the transdermal delivery was investigated to the treatment of psoriasis via modulating the IL6-HIF-1α-VEGF axis. The results demonstrated that DTX-LP-G cumulatively released a much higher amount of drug into the skin than that from DTX-loaded liposomes (DTX-LPs) and DTX-loaded gel (DTX-G). DTX-LP-G was also the most efficient in scavenging hydrogen peroxide free radicals in vitro. In a mouse model of psoriasis, DTX-LP-G acted as a preliminary therapeutic agent for psoriasis in terms of apparent evaluation, splenomegaly, suppression of MDA content in skin tissue, and down-regulated the expression of IL6, HIF-1α, and VEGF to control the proliferation of vessels, except for a less pronounced effect on the stratum corneum. In addition, enrichment analysis can speculate that DTX also treated psoriasis by resisting the production of keratin-forming cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.